Post-doctoral researcher Jess Beach, who specialises in ovarian cancer, moved across the globe to work with Peter Mac’s Professor David Bowtell. She has just started her first clinical trial in ovarian cancer: Targeting the C1 Subtype of High Grade Serous Ovarian Cancer (BEACON).
Incorrect antibiotic allergy labels pose a significant public health issue and more needs to be done to ensure Australia’s most vulnerable patients are not incorrectly diverted to second-line drugs. In a perspective article published in the Medical Journal of Australia today, Dr Jason Trubiano says incorrect antibiotic allergy labels frequently prevent the use of appropriate narrow spectrum penicillin and targeted antibiotic therapies and often it is the sickest patients who suffer.
Peter Mac scientists who were investigating how tumours evade the immune system have identified a potent and previously underappreciated way that cancer cells are destroyed, involving Tumour Necrosis Factor (TNF).
The Peter MacCallum Cancer Centre acknowledges the traditional
owners of the land on which our five sites are located throughout Victoria.
We recognise their strength and resilience and pay our respects
to their Elders past and present.